ClinicalTrials.gg

Lymphoma, Large B-Cell, Diffuse clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,872 studies for Lymphoma, Large B-Cell, Diffuse across more than 10 countries. 359 are recruiting or about to start. 947 of them are mainly about Lymphoma, Large B-Cell, Diffuse (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 2,173 studies for Lymphoma, Large B-Cell, Diffuse. How that becomes 1,872 here

This page counts the studies the registry files under Lymphoma, Large B-Cell, Diffuse, and those it files under no condition that list Lymphoma, Large B-Cell, Diffusethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,173Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −101List Lymphoma, Large B-Cell, Diffuse as a condition, but the registry did not file them under itMost often written as “DLBCL - Diffuse Large B Cell Lymphoma” (42), “Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma” (10), and “Diffuse Large B Cell Lymphoma Refractory” (5). The registry filed them under other conditions only, most often Dendritic Cell Sarcoma, Interdigitating (52) and Lymphoma (25).
  3. −200Match it another way121 name it in the title, 28 in a keyword, and 51 by a synonym or other text the search reads.
  4. 1,872The count on this page39 of them list Lymphoma, Large B-Cell, Diffuse in their own words; the registry filed them under no condition.

Status

Completed
873
Recruiting
266
Terminated
256
Status unknown
170
Active, not recruiting
131
Not yet recruiting
83

Phase

Phase 2
902
Phase 1
685
Phase 3
187
Early Phase 1
21
Phase 4
14

Where

United States
1,131
China
306
France
182
Italy
166
United Kingdom
130
Spain
128

Who develops what

Add Lymphoma, Large B-Cell, Diffuse to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 36 programs from 31 companies, 25 with this as their studies’ main aim; 10 with a live phase 3 study; 6 primary completions in the next 12 months. Compare BeOne Medicines, Eli Lilly and Lupeng Pharmaceutical here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RituximabRecent, repeated
Evidence
  • NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Rituximab” · registered Oct 2026
  • NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Rituximab” · registered Sep 2026
  • NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Rituximab” · registered Jul 2026
  • NCT07189065 · Lupeng Pharmaceutical Ltd. · Phase 2 · live · comparator · “Rituximab” · registered Sep 2025
  • NCT06929624 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Rituximab Injection” · registered Apr 2025
Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others1113 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Cyclophosphamide” · registered Sep 2026
  • NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Cyclophosphamid” · registered Jul 2026
  • NCT07124936 · huadong medicine · Phase 2 · live · background · “Cyclophosphamide” · registered Aug 2025
  • NCT07035379 · Zhejiang Teruisi Pharmaceutical Inc. · Phase 2 · live · background · “Cyclophosphamide” · registered Jun 2025
  • NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Cyclophosphamide” · registered Mar 2025
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed1011 studies
DoxorubicinRecent, repeated
Evidence
  • NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Doxorubicin” · registered Jul 2026
  • NCT07124936 · huadong medicine · Phase 2 · live · background · “Doxorubicin” · registered Aug 2025
  • NCT07035379 · Zhejiang Teruisi Pharmaceutical Inc. · Phase 2 · live · background · “Doxorubicin” · registered Jun 2025
  • NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Doxorubicin” · registered Mar 2025
  • NCT06717347 · Merck & Co., Inc · Phase 3 · live · background · “Doxorubicin” · registered Dec 2024
Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed67 studies
LenalidomideRecent, repeated
Evidence
  • NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Lenalidomide” · registered Oct 2026
  • NCT07189065 · Lupeng Pharmaceutical Ltd. · Phase 2 · live · comparator · “Lenalidomide” · registered Sep 2025
  • NCT05660967 · Genmab · Phase 2 · background · “Lenalidomide” · registered Nov 2022
  • NCT05626322 · Pfizer · Phase 2 · background · “Lenalidomide” · registered Nov 2022
  • NCT05328102 · Xencor, Inc. · Phase 2 · background · “Lenalidomide” · registered Apr 2022
Bristol-Myers Squibb61% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 4 generics authorized67 studies
GemcitabineRecent, repeated
Evidence
  • NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Gemcitabine Hydrochloride” · registered Sep 2026
  • NCT07124936 · huadong medicine · Phase 2 · live · background · “Gemcitabine” · registered Aug 2025
  • NCT06929624 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Gemcitabine Hydrochloride for Injection” · registered Apr 2025
  • NCT06806033 · Hoffmann-La Roche · Phase 2 · live · background · “Gemcitabine” · registered Jan 2025
  • NCT06792253 · BeBetter Med Inc · Phase 3 · live · comparator · “Gemcitabine Hydrochloride for Injection” · registered Jan 2025
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed55 studies
PrednisoneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Prednisone” · registered Jul 2026
  • NCT07124936 · huadong medicine · Phase 2 · live · background · “Prednisone” · registered Aug 2025
  • NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Prednisone” · registered Mar 2025
  • NCT06717347 · Merck & Co., Inc · Phase 3 · live · background · “Prednisone” · registered Dec 2024
  • NCT06091865 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Prednisone/Prednisolone” · registered Oct 2023
Johnson & Johnson11% of its industry studies56 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Sep 2026
  • NCT07124936 · huadong medicine · Phase 2 · live · background · “Oxaliplatin” · registered Aug 2025
  • NCT06929624 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · background · “Oxaliplatin Injection” · registered Apr 2025
  • NCT06806033 · Hoffmann-La Roche · Phase 2 · live · background · “Oxaliplatin” · registered Jan 2025
  • NCT06792253 · BeBetter Med Inc · Phase 3 · live · comparator · “Oxaliplatin Injection” · registered Jan 2025
Sanofi35% of its industry studies55 studies
VincristineRecent, repeated
Evidence
  • NCT07818499 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Vincristine Sulfate” · registered Sep 2026
  • NCT07712588 · Dizal Pharmaceuticals · Phase 3 · live · background · “Vincristine” · registered Jul 2026
  • NCT06717347 · Merck & Co., Inc · Phase 3 · live · comparator · “Vincristine” · registered Dec 2024
  • NCT06091865 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Vincristine” · registered Oct 2023
  • NCT04824092 · Incyte Corporation · Phase 3 · live · background · “Vincristine” · registered Mar 2021
Bristol-Myers Squibb9% of its industry studies44 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT06093841 · Shanghai Ming Ju Biotechnology Co., Ltd. · Phase 2 · live · background · “Fludarabine” · registered Oct 2023
  • NCT05972720 · CARGO Therapeutics · Phase 2 · background · “Fludarabine (Conditional therapy)” · registered Jul 2023
  • NCT05826535 · Lyell Immunopharma, Inc. · Phase 2 · live · background · “Fludarabine” · registered Mar 2023
  • NCT04836507 · Curocell Inc. · Phase 2 · live · background · “Fludarabine” · registered Apr 2021
  • NCT04792489 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Fludarabine” · registered Feb 2021
Beijing Biotech18% of its industry studies33 studies
PrednisoloneRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07035379 · Zhejiang Teruisi Pharmaceutical Inc. · Phase 2 · live · background · “Prednisolone” · registered Jun 2025
  • NCT06890884 · Merck & Co., Inc · Phase 2 · live · background · “Prednisolone” · registered Mar 2025
  • NCT06717347 · Merck & Co., Inc · Phase 3 · live · background · “Prednisolone” · registered Dec 2024
  • NCT06091865 · Regeneron Pharmaceuticals · Phase 3 · live · background · “Prednisone/Prednisolone” · registered Oct 2023
  • NCT01897571 · Ipsen · Phase 2 · background · “Prednisolone” · registered Jun 2013
Sanofi15% of its industry studies34 studies
bendamustineRecent, repeated
Evidence
  • NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Bendamustine” · registered Oct 2026
  • NCT07189065 · Lupeng Pharmaceutical Ltd. · Phase 2 · live · comparator · “Bendamustine” · registered Sep 2025
  • NCT04792489 · Miltenyi Biomedicine GmbH · Phase 2 · live · background · “Bendamustine” · registered Feb 2021
  • NCT04663347 · Genmab · Phase 2 · live · background · “rituximab and bendamustine” · registered Oct 2020
  • NCT04607772 · Karyopharm Therapeutics Inc · Phase 2 · background · “Bendamustine” · registered Oct 2020
Teva Pharmaceutical Industries, Ltd.25% of its industry studiesUS: off-patent, 3 generics marketed22 studies
polatuzumab vedotinRecent, repeated
Evidence
  • NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Polatuzumab vedotin” · registered Oct 2026
  • NCT06890884 · Merck & Co., Inc · Phase 2 · live · comparator · “Polatuzumab vedotin” · registered Mar 2025
  • NCT05283720 · Genmab · Phase 2 · live · background · “Polatuzumab Vedotin” · registered Mar 2022
  • NCT04607772 · Karyopharm Therapeutics Inc · Phase 2 · background · “Polatuzumab Vedotin” · registered Oct 2020
Hoffmann-La Roche92% of its industry studiesUS: Hoffmann-La Roche (FDA 2019)EU: Hoffmann-La Roche (EMA 2020)23 studies
tafasitamabRecent, repeated
Evidence
  • NCT07917754 · Merck & Co., Inc · Phase 3 · live · comparator · “Tafasitamab” · registered Oct 2026
  • NCT05328102 · Xencor, Inc. · Phase 2 · background · “Tafasitamab” · registered Apr 2022
  • NCT04607772 · Karyopharm Therapeutics Inc · Phase 2 · background · “Tafasitamab” · registered Oct 2020
Incyte Corporation47% of its industry studiesUS: Novartis (FDA 2020)EU: Incyte Corporation (EMA 2021)22 studies

19 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Anti-CD79b Antibody-drug Conjugate SHR-A1912☆ Track1 live phase-3 study: NCT06929624Jiangsu HengRui Medicine Co., Ltd.
zilovertamab vedotin☆ Track2 live phase-3 studies: NCT06717347, NCT05139017Merck & Co., Inc
epcoritamabApproved: US 2023 · EU 2023☆ Track3 live phase-3 studies: NCT07226752, NCT04628494, NCT06508658Genmab
glofitamabApproved: US 2023 · EU 2023☆ Track1 live phase-3 study: NCT04408638Hoffmann-La Roche
BTK Inhibitor HMPL-760☆ Track1 live phase-3 study: NCT07409428HUTCHMED

The 5 in phase 3 with the nearest primary completion, of 36 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (6)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jan 2027 est.Anti-CD20 Antibody-drug Conjugate TRS005 · Zhejiang Teruisi Pharmaceutical Inc. · Phase 2 main aimNCT06886139 A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. — primary endpoint: ORR, Objective Response Rate · 139 enrolled
  • Mar 2027 est.epcoritamab · Genmab · Phase 2 main aimNCT05451810 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma — primary endpoint: Percentage of Participants Experiencing Grade 3 or Higher Cytokine Release Syndrome (CRS) Events · 184 enrolled
  • Mar 2027 est.Anti-CD79b Antibody-drug Conjugate SHR-A1912 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 main aimadded to Rituximabadded to Gemcitabineadded to OxaliplatinNCT06929624 A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma — primary endpoint: Complete response rate (CRR) · 282 enrolled

3 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Lymphoma, Large B-Cell, Diffuse studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 42 open · Antimetabolites 21 open · Antibody-drug conjugates (ADCs) 19 open · Alkylating agents 18 open · HDAC inhibitors 14 open

Coming up

131studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger. 25 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 7 (3%) take healthy volunteers.

Recruiting studies that take each age, of 266
AgeWomenMen
1015 (6%)15 (6%)
18237 (89%)237 (89%)
30239 (90%)239 (90%)
40237 (89%)237 (89%)
50236 (89%)236 (89%)
65248 (93%)248 (93%)
75244 (92%)244 (92%)
85196 (74%)196 (74%)

Across all 1,872 studies, recruiting or not: 24% stop at 75 or younger and 11% at 65; 17% take children; <1% are for women only and <1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoma, Large B-Cell, Diffuse studies take

Of 264 phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 153 mo35–80 · 195 studies49 mo33–71 · 84 studies57 mo39–83 · 111 studies
Phase 1/270 mo50–98 · 108 studies75 mo54–99 · 51 studies66 mo46–94 · 57 studies
Phase 253 mo35–85 · 264 studies37 mo22–57 · 54 studies57 mo40–96 · 210 studies
Phase 357 mo39–99 · 73 studies53 mo36–82 · 37 studies—
Interventional, no phase73 mo42–137 · 41 studies—73 mo42–144 · 40 studies
Observational52 mo29–114 · 66 studies—40 mo26–114 · 52 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered13

Show 8 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,872. Browse all 1,872 → or search them.